Thermo Fisher, Catalent, Oxford Biomedica, and Lonza Invest in Next-Generation Viral Vector and Plasmid DNA Production to Support Rapid Gene Therapy Pipeline Expansion

The Viral Vector and Plasmid DNA Manufacturing Market size was valued USD 2.85 billion in 2021 and is estimated to reach USD billion by 2031, growing at a CAGR of 14.2% during the forecast period 2024-2031.

Viral vector and plasmid DNA manufacturing plays a critical role in the development of cell and gene therapies, vaccines, and advanced biologics. Viral vectors such as adenoviruses, retroviruses, adeno-associated viruses (AAV), and lentiviruses, along with plasmid DNA, are essential for delivering genetic material in therapeutic and vaccine applications. The global market is experiencing robust growth, driven by rising investments in gene therapy, increasing approvals of advanced therapies, and expanding use of DNA-based vaccines.

📌 Download Sample Report to Identify Emerging Deals & Opportunities in the Viral Vector and Plasmid DNA Manufacturing Market Landscape:- https://datamintelligence.com/download-sample/viral-vector-and-plasmid-dna-manufacturing-market?rk

☛ Viral Vector and Plasmid DNA Manufacturing Market Recent Developments 2025:

United States: Recent Industry Developments

✅ In August 2025, Thermo Fisher Scientific expanded its viral vector and plasmid DNA production capacity at its Massachusetts facility, supporting cell and gene therapy pipelines.

✅ In July 2025, Catalent announced upgrades to its Maryland gene therapy facility, focusing on large-scale plasmid DNA production for clinical and commercial supply.

✅ In June 2025, Charles River Laboratories partnered with biotech firms to accelerate viral vector manufacturing, emphasizing speed-to-clinic capabilities.

Europe: Recent Industry Developments

✅ In July 2025, Oxford Biomedica launched a new state-of-the-art viral vector manufacturing facility in the UK, boosting capacity for lentiviral and adenoviral vectors.

✅ In June 2025, Lonza expanded its plasmid DNA manufacturing operations in Switzerland, strengthening its position as a key CDMO for gene therapies.

✅ In May 2025, Bavarian Nordic announced investments in viral vector production platforms, supporting vaccine development across European markets.

Japan: Recent Industry Developments

✅ In July 2025, Takara Bio Inc. expanded its viral vector and plasmid DNA manufacturing services for both domestic and global biopharma companies.

✅ In June 2025, FUJIFILM Diosynth Biotechnologies Japan invested in next-generation gene therapy manufacturing technologies, enhancing scalability and regulatory compliance.

✅ In May 2025, Sysmex Corporation partnered with academic institutions to strengthen viral vector R&D and production capabilities for advanced therapies.

☛ Viral Vector and Plasmid DNA Manufacturing Market Trends:

Rising Demand for Gene Therapy: Increasing prevalence of genetic disorders, cancer, and rare diseases is fueling demand for viral vectors and plasmid DNA as core components of advanced therapies.

Technological Advancements: Innovations in upstream bioprocessing, large-scale manufacturing, and suspension cell culture systems are improving yields and cost efficiency.

COVID-19 and Beyond: The pandemic accelerated adoption of DNA-based and viral vector vaccines, boosting infrastructure investments that continue to support the market post-pandemic.

Outsourcing and CDMO Growth: Biopharma companies are increasingly outsourcing production to contract development and manufacturing organizations (CDMOs) to access specialized expertise and scale.

Regional Insights: North America and Europe dominate the market due to strong biotech ecosystems, while Asia-Pacific is emerging rapidly with government investments, rising clinical trials, and expanding biomanufacturing capacity.

Challenges: High production costs, regulatory complexities, and quality control issues in large-scale production remain significant hurdles.

Strategic Initiatives: Companies are focusing on expansion of manufacturing facilities, partnerships, and acquisitions to meet the rising global demand for clinical and commercial-scale viral vectors and plasmid DNA.

☛ Viral Vector and Plasmid DNA Manufacturing Market Competitve Landscape:

Brammer Bio, Cobra Biologics, Cell and Gene Therapy Catapult, FinVector Vision Therapies, Fujifilm Diosynth Biotechnologies, SIRION Biotech, Merck KGaA Inc., Thermo Fisher Scientific, and Uniqure NV.

Research Methodology

We follow a hybrid research approach, combining qualitative insights with rigorous quantitative analysis to deliver reliable and comprehensive market intelligence. Our process begins with extensive secondary research, drawing on trusted industry reports, proprietary databases, and credible market sources. This is then reinforced through targeted primary research, including structured surveys and in-depth interviews with industry leaders, subject matter experts, and key market participants.

📌 Request a Customized Market Report - Tailored insights to match your business goals: https://datamintelligence.com/customize/viral-vector-and-plasmid-dna-manufacturing-market

☛ Segment Covered in the Viral Vector and Plasmid DNA Manufacturing Market:

By Product Type: Plasmid DNA, Viral Vector, Non-Viral Vector

By Application: Cancer, Genetic Disorder, Infectious diseases, Other Diseases

☛ This Report Includes:

✔ Comprehensive go-to-market strategies with actionable insights.

✔ Unbiased evaluation of overall market performance.

✔ Deep-dive analysis into development trends, competitive landscape, supply-demand dynamics, YoY growth, benchmarking, vendor mapping, market access, and overall progress.

✔ Tailored regional and country-level reports with detailed localized analysis available on request.

✔ Identification of niche segments and high-growth regions presenting strong opportunities.

✔ Accurate regional forecasts using both top-down and bottom-up approaches.

📌 Get Corporate Access to Live Viral Vector and Plasmid DNA Manufacturing Industry Intelligence Database: https://www.datamintelligence.com/buy-now-page?report=viral-vector-and-plasmid-dna-manufacturing-market

☛ Regional Analysis for Viral Vector and Plasmid DNA Manufacturing Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

☛ Frequently asked questions:

➠ What is the global sales, production, consumption, import, and export value of the Viral Vector and Plasmid DNA Manufacturing Market?
➠ Who are the key global manufacturers, and what is their operational performance?
➠ What are the major opportunities and threats in the global Viral Vector and Plasmid DNA Manufacturing Market?
➠ Which product types or end-users show the most growth potential and market share?
➠ What challenges and constraints are impacting the Viral Vector and Plasmid DNA Manufacturing Market?
➠ What sales, marketing, and distribution channels are used globally?

📌 Request for 2 Days FREE Trial Access: https://www.datamintelligence.com/reports-subscription

☛ Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

☛ Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.